[go: up one dir, main page]

DK2037899T3 - Nanopartikler til nukleinsyreafgivelse - Google Patents

Nanopartikler til nukleinsyreafgivelse

Info

Publication number
DK2037899T3
DK2037899T3 DK07764504.2T DK07764504T DK2037899T3 DK 2037899 T3 DK2037899 T3 DK 2037899T3 DK 07764504 T DK07764504 T DK 07764504T DK 2037899 T3 DK2037899 T3 DK 2037899T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
acid delivery
delivery nanoparticles
nanoparticles
chitosan
Prior art date
Application number
DK07764504.2T
Other languages
English (en)
Inventor
Flemming Besenbacher
Kenneth Alan Howard
Joergen Kjems
Xiudong Liu
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Application granted granted Critical
Publication of DK2037899T3 publication Critical patent/DK2037899T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK07764504.2T 2006-07-07 2007-07-06 Nanopartikler til nukleinsyreafgivelse DK2037899T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81920906P 2006-07-07 2006-07-07
PCT/DK2007/050084 WO2008003329A2 (en) 2006-07-07 2007-07-06 Nanoparticles for nucleic acid delivery

Publications (1)

Publication Number Publication Date
DK2037899T3 true DK2037899T3 (da) 2011-05-09

Family

ID=38754461

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07764504.2T DK2037899T3 (da) 2006-07-07 2007-07-06 Nanopartikler til nukleinsyreafgivelse

Country Status (8)

Country Link
US (1) US20100015232A1 (da)
EP (3) EP2037899B1 (da)
AT (1) ATE503469T1 (da)
CA (1) CA2706124A1 (da)
DE (1) DE602007013559D1 (da)
DK (1) DK2037899T3 (da)
ES (1) ES2362376T3 (da)
WO (1) WO2008003329A2 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875449B2 (en) 2006-09-15 2011-01-25 Fmc Biopolymer As Oligonucleotide non-viral delivery systems
WO2009048958A2 (en) * 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
EP3252068B1 (en) 2009-10-12 2025-07-02 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
FR2963351B1 (fr) * 2010-07-30 2013-03-08 Univ Claude Bernard Lyon Particules formees d'un complexe polyelectrolyte de chitosane et d'un polysaccharide anionique, presentant une stabilite amelioree
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012094574A2 (en) * 2011-01-06 2012-07-12 The Johns Hopkins University Stabilized polyribonucleotide nanoparticles
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
EP2694042A4 (en) * 2011-04-04 2015-06-10 Univ Nebraska Activated Nucleoside Analog Conjugates and Methods of Use
US20150087689A1 (en) 2011-05-24 2015-03-26 Polyvalor, Limited Partnership COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF siRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES
US8841272B2 (en) * 2011-05-31 2014-09-23 Kansas State University Research Foundation Double-stranded RNA-based nanoparticles for insect gene silencing
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2014039627A1 (en) 2012-09-05 2014-03-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
EP3151856B1 (en) * 2014-06-06 2019-08-07 Merck Patent GmbH Antigen-loaded chitosan nanoparticles for immunotherapy
WO2016011222A2 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
US9724307B2 (en) 2015-02-24 2017-08-08 San Heh Pharmaceutical Corporation Crosslinked nanoparticle composition
US12109274B2 (en) 2015-09-17 2024-10-08 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
BR112018071997A2 (pt) * 2016-04-26 2019-02-12 Viaqua Therapeutics Ltd nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
EP3552632B1 (en) * 2016-12-07 2023-07-12 Stelic Institute & Co., Inc. Medicinal composition for treating and preventing inflammatory bowel disease
BR112020020870A2 (pt) 2018-07-03 2021-04-06 Embrapa-Empresa Brasileira De Pesquisa Agropecuaria Pesticida
CN110396524B (zh) * 2019-05-31 2023-05-02 海南大学 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途
KR102604882B1 (ko) * 2021-07-01 2023-11-21 인천대학교 산학협력단 신규 특이적 항암 및 항염증 siRNA 및 이의 용도
WO2023084510A1 (en) 2021-11-09 2023-05-19 Viaqua Therapeutics Ltd. Compositions for aquaculturing
IT202100032393A1 (it) 2021-12-23 2023-06-23 Torino Politecnico Metodo per la preparazione di nanoparticelle polimeriche ibride per il rilascio di farmaci oligonucleotidici nelle terapie farmacologiche a scopo rigenerativo, curativo e preventivo
CN115992131A (zh) * 2022-07-22 2023-04-21 江苏省农业科学院 一种纳米化壳聚糖/dsGRK复合体及其制备方法和应用
WO2024182707A1 (en) 2023-03-02 2024-09-06 Krystal Biotech, Inc. Interleukin-2 and interleukin-12 for cancer therapy
CN118304423B (zh) * 2023-05-25 2024-10-11 无锡市第二人民医院 多层级壳聚糖明胶颗粒载P4HA1 siRNA通过抑制细胞EMT治疗脑胶质瘤的研究

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
NO317653B1 (no) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20040138154A1 (en) * 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
US7875449B2 (en) * 2006-09-15 2011-01-25 Fmc Biopolymer As Oligonucleotide non-viral delivery systems

Also Published As

Publication number Publication date
EP2397123A1 (en) 2011-12-21
CA2706124A1 (en) 2008-01-10
WO2008003329A3 (en) 2008-02-21
ES2362376T3 (es) 2011-07-04
DE602007013559D1 (de) 2011-05-12
ATE503469T1 (de) 2011-04-15
US20100015232A1 (en) 2010-01-21
EP2295045A1 (en) 2011-03-16
EP2037899B1 (en) 2011-03-30
WO2008003329A2 (en) 2008-01-10
EP2037899A2 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
DK2037899T3 (da) Nanopartikler til nukleinsyreafgivelse
WO2008151022A3 (en) Nucleic acid nanoparticles and uses therefor
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
HK1200837A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
WO2013143700A3 (en) Artificial nucleic acid molecules comprising a 5'top utr
WO2008115851A3 (en) Rnai therapeutic for respiratory virus infection
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2010014895A3 (en) Nanoparticle compositions for nucleic acids delivery system
EP4385568A3 (en) Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
WO2009129319A3 (en) Silencing of csn5 gene expression using interfering rna
WO2013165816A3 (en) SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2006110688A3 (en) Rnai therapeutic for respiratory virus infection
EP4279610A3 (en) Ribonucleic acid purification
WO2010048228A3 (en) Compositions and methods for inhibiting expression of transthyretin
HK1208227A1 (en) Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
WO2008134761A3 (en) Modification of biological targeting groups for the treatment of cancer
HK1203077A1 (en) Modified nucleoside, nucleotide, and nucleic acid compositions
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
MX2014006136A (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
LT3098239T (lt) Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui
WO2007131495A3 (de) Multimer zur immunstimulation